Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.59 |
| ▸ | HPGD | P15428 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5437272 | 0.99 | KDM4E (0.60) | KDM4EHSD17B10HPGDALDH1A1TSHR | |
| SCHEMBL3976165 | 0.98 | KDM4E (0.59) | KDM4EHSD17B10HPGDALDH1A1TSHR | |
| Trifluoroacetic Acid SCHEMBL3982421 | 0.93 | KDM4E (0.55) | KDM4EHSD17B10HPGDALDH1A1TSHR | |
| SCHEMBL4388671 | 0.89 | KDM4E (0.55) | KDM4EHSD17B10HPGDALDH1A1TSHR | |
| SCHEMBL4176893 | 0.88 | KDM4E (0.61) | KDM4EHSD17B10HPGDALDH1A1TSHR | |
| SCHEMBL3843176 | 0.88 | KDM4E (0.56) | KDM4EHSD17B10HPGDALDH1A1TSHR | |
| SCHEMBL3976168 | 0.87 | KDM4E (0.46) | KDM4EHSD17B10HPGDALDH1A1TSHR | |
| SCHEMBL13997241 | 0.87 | HPGD (0.55) | KDM4EHSD17B10HPGDALDH1A1TSHR | |
| SCHEMBL3978265 | 0.85 | LMNA (0.65) | KDM4EHSD17B10HPGDALDH1A1TSHR | |
| Formic Acid SCHEMBL4385081 | 0.85 | KDM4E (0.53) | KDM4EHSD17B10HPGDALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569550-B2 | 14 and 15 membered ring compounds | GLAXO GROUP LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| US-20090062218-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20070293472-A1 | Novel 14 and 15 Membered Ring Compounds | GLAXO GROUP LIMITED (GB) | 2007-12-20 | — | — | US | disclosed |
| US-20070185117-A1 | Novel 14 and 15 membrered ring compounds | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1628989-B1 | NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS | GLAXO GROUP LTD (GB) | 2006-12-20 | — | — | EP | disclosed |
| EP-1628988-B1 | NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS | GLAXO GROUP LTD (GB) | 2006-10-04 | — | — | EP | disclosed |
| EP-1628988-A1 | NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-03-01 | — | — | EP | disclosed |
| EP-1628989-A1 | NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004101584-A1 | MACROLIDES SUBSTITUTED AT THE 3-POSITION HAVING ANTIMICROBIAL ACTIVITY | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004101587-A1 | NOVEL 14 AND 15 MEMBERRED-RING COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004101586-A1 | NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185117-A1 | Novel 14 and 15 membrered ring compounds | CYP51A1, LSS, IL17A | KDM4E 3840/4885HSD17B10 668/4885HPGD 1267/4885 |
| US-20070293472-A1 | Novel 14 and 15 Membered Ring Compounds | IL17A, CYP51A1, IL15 | KDM4E 3390/4885HSD17B10 287/4885HPGD 1054/4885 |
| US-20090062218-A1 | MACROLONE COMPOUNDS | CYP51A1, MRPL21, MYD88 | KDM4E 3897/4885HSD17B10 300/4885HPGD 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.